Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2019

View Archived Issues

Acetyl CoA and metabolic health

Synthesis and in vitro characterization of new analogues of manogepix against Cryptococcus spp.

New prostate cancer treatment strategy may overcome resistance

Durvalumab does not improve efficacy of azacitidine in phase II AML/MDS trial

AST-008 demonstrates activity in patients with MCC

CBDVHS demonstrates enhanced antiseizure activity compared to CBD

Lilly initiates phase III LIBRETTO-431 study of selpercatinib

VRG-50014 rescues ALS phenotypes in preclinical models

NCKAP1 as a new therapeutic target in ALS

CYT-0853 demonstrates promising activity in models of autoimmune disease

Discovery and preclinical characterization of novel DHODH inhibitors for AML

Novel FVIII mimetic bispecific antibody Mim8 exhibits preclinical efficacy against hemophilia A

Positive early phase I data for Genmab's CD3xCD20 bispecific antibody GEN-3013

Transgene and BioInvent report preclinical data on BT-001 for solid tumors

BAR Pharmaceuticals describes new NR1H4 antagonists

Beijing Scitech-Mq Pharmaceuticals patents EGFR and/or ALK inhibitors

3M Pharmaceuticals presents cytokine-releasing compounds for infections

Roche and Genentech identify SCN9A blockers

Helix begins phase Ib/II study of L-DOS47 in previously treated pancreatic cancer

Canadian researchers synthesize new androgen receptor antagonists

Xintela's function-blocking antibody suppresses growth of glioblastoma tumors in preclinical model

Transgene opens enrollment in phase I study of TG-4050 for ovarian cancer

Emergex advances early development of vaccine candidate against F. tularensis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...